Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor

BACKGROUND: Endothelin receptor antagonists inhibit the progression of many cancers, but research into their influence on glioma has been limited. METHODS: We treated glioma cell lines, LN-229 and SW1088, and melanoma cell lines, A375 and WM35, with two endothelin receptor type B (ETRB)-specific ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Montgomery, Jennifer P, Patterson, Paul H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613414/
https://www.ncbi.nlm.nih.gov/pubmed/19040731
http://dx.doi.org/10.1186/1471-2407-8-354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613414/
https://www.ncbi.nlm.nih.gov/pubmed/19040731
http://dx.doi.org/10.1186/1471-2407-8-354

Ejemplares similares